Edgewise Therapeutics (EWTX) Corporate Presentation summary

Strategic focus and pipeline

• Global leader in muscle disease therapeutics with deep expertise in muscle physiology and a holistic approach to muscle protection.

• Advancing sevasemten for Becker and Duchenne muscular dystrophy, and EDG-7500 for hypertrophic cardiomyopathy (HCM).

• Pipeline includes additional cardiometabolic targets in discovery and development.

• Mission-driven to address unmet needs in severe muscle conditions, with patient and family engagement in development.

Sevasemten in muscular dystrophy

• Sevasemten is a first-in-class fast myofiber myosin inhibitor designed to protect against contraction-induced muscle injury in Becker and Duchenne muscular dystrophy.

• Clinical trials (ARCH, CANYON, GRAND CANYON, DUNE, LYNX, FOX) are ongoing, targeting both Becker and Duchenne populations.

• ARCH study showed sevasemten was well-tolerated, stabilized or improved NSAA scores over 24 months, and reduced muscle damage biomarkers.

• DUNE exercise challenge study demonstrated significant reductions in muscle injury biomarkers post-exercise.

• CANYON Phase 2 topline data expected in 4Q24; GRAND CANYON pivotal cohort is powered to detect meaningful clinical benefit.

Market opportunity and patient impact

• No approved therapies for Becker; ~12,000 patients in US, EU-5, and Japan, with significant unmet need.

• Duchenne market estimated at $1.1B in the US, with potential to grow to $5B; ~35,000 patients in US, EU-5, and Japan.

• Sevasemten positioned as a foundational, mutation-agnostic therapy for Duchenne, addressing all ambulatory boys regardless of prior treatment.